Published Date: 07 Jun 2024
Enhancing quality of life was another benefit of anticholinergic oxybutynin for ADT-using patients.
Read Full NewsuniQure navigates FDA's unexpected shift on AMT-130, aiming for accelerated approval for Huntington's disease despite recent regulatory challenges.
Mind Moments®, a podcast from NeurologyLive®, brings you an exclusive interview with Christina Briscoe, MD. [LISTEN TIME: 24 minutes]
Over the first 3 months of treatment, over 60% of patients with migraine treated with galcanezumab attained at least a 50% reduction in monthly migraine or headache days.
Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending November 28, 2025.
Cheung explores the effect of sparsentan on urinary biomarkers in treatment-naive patients with IgA nephropathy.
ACR Convergence 2025 Recap: Late-Breaking Trials to Know
Tezepelumab Drastically Reduces OCS Use for Asthma in Open-Label Trial
1.
In Sickle Cell Disease, Lovo-Cel is "Life-Changing, Transformative.".
2.
Dual-action mRNA vaccine takes aim at aggressive skin cancer
3.
Scientists hail the cervical cancer treatment as the most remarkable breakthrough in 20 years.
4.
From 40 to 74, the US Preventive Services Task Force advises every two years for screening mammography.
5.
WHO launches plan for free child cancer medicines
1.
Immuno-Oncology in Daily Practice: Transforming Cancer Care One Patient at a Time
2.
The Importance of Iron Rich Foods in Preventing and Treating Anemia
3.
Chondroma: What it is and How it Affects Your Health
4.
Priming Agents: A Novel Approach to Enhancing Cell-Free DNA Detection in Liquid Biopsies
5.
Unlocking the Power of Cryoprecipitate: A Comprehensive Guide
1.
International Lung Cancer Congress®
2.
Genito-Urinary Oncology Summit 2026
3.
Future NRG Oncology Meeting
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
Virtual Case Study on Elephantiasis of Lower Limb- An Initiative by Hidoc Dr.
2.
Untangling The Best Treatment Approaches For ALK Positive Lung Cancer - Part VI
3.
Beyond the Mutation: Addressing the Unmet Needs in ALK-Positive NSCLC
4.
INO-VATE: The Long-Term Overall Survival Analysis in Iontuzumab-Treated Patients
5.
Efficient Management of First line ALK-rearranged NSCLC - Part VIII
© Copyright 2025 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation